These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36289896)

  • 1. Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype.
    González-Pérez R; Poza-Guedes P; Mederos-Luis E; Sánchez-Machín I
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
    Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
    Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
    Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
    World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.
    Israel E; Canonica GW; Brusselle G; Yang S; Howarth PH; Martin AL; Koufopoulou M; Smith SG; Alfonso-Cristancho R
    J Asthma; 2022 Nov; 59(11):2201-2217. PubMed ID: 34951336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.
    Malik B; Bartlett NW; Upham JW; Nichol KS; Harrington J; Wark PAB
    Respirology; 2023 Aug; 28(8):758-766. PubMed ID: 37114915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
    Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
    J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
    Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
    J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review.
    Dighriri IM; Alnughaythir AI; Albesisi AA; Alhuwaimel DI; Alotaibi AS; Alghowaidi LA; Almalki FH; Al-Bukhari JN; Alshammari TR; Alwathnani FH; Alghamdi AA; Alghamdi AA; Alshehri SD; Mahnashi NY; Abu Jamilah HA
    Cureus; 2023 Dec; 15(12):e49781. PubMed ID: 38161547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.
    Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
    Respir Investig; 2021 Jul; 59(4):478-486. PubMed ID: 33849780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.